Next Medical

What Next Medical does

Next Medical (operating as NextMed) was a New York-based, privately-held telemedicine company founded in 2021 that built and operated a direct-to-consumer weight loss platform focused on GLP-1 medications such as Mounjaro, Ozempic, and semaglutide. Patients self-enrolled online, completed intake questionnaires, underwent lab work at partner facilities (Labcorp and Quest Diagnostics), consulted with physicians via telemedicine, and received prescriptions at their preferred pharmacy, with the company handling insurance prior authorization on their behalf.

The core platform combined a telemedicine consultation portal, an insurance navigation and prior authorization automation layer, lab ordering integration with Labcorp and Quest, prescription management, and 24/7 customer support. Its proprietary differentiators centered on operational speed — reducing prior authorization timelines from an industry-standard ~3 weeks to as little as 4 days — and on integrated lab-to-pharmacy workflows that lowered patient friction. Revenue was generated primarily through insurance billing for consultations and prescriptions, with patients reporting out-of-pocket medication costs as low as $3–$25 when coverage was obtained, supplemented by subscription fees. The company raised a total of $15M in funding (including approximately $7M from K5 Global in March 2022), declined a $100M acquisition offer, and scaled to 1,000+ employees across 13 countries while serving 390,000+ customers.

NextMed discontinued operations after FDA-recognized shortages for GLP-1 drugs came to an end, citing the closure as a strategic decision tied to the drug supply environment rather than demand.

Name

Next Medical

Website

https://nextmed.com

Company type

Private

Founded year

2021

Operating status

Closed

Headcount range

11–50 employees

Short description

NextMed was a New York-based direct-to-consumer telemedicine platform that connected patients to physicians for GLP-1 weight loss prescriptions, lab testing via Labcorp and Quest, insurance prior authorization, and ongoing care, before shutting down following the end of FDA-recognized GLP-1 drug shortages.

Ownership category

akta.pro rank

Product category

Telemedicine Weight Management

NAICS

Other Ambulatory Health Care Services (6219)

SIC

Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Prescription-Based Digital Clinics (Condition-Specific Rx Programs) (HLALAAAD)

akta.pro secondary industry

Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing (HLALAIAH)

Keywords

• Telemedicine services
• Weight loss programs
• GLP-1 medications
• Online healthcare
• Prescription management

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Telemedicine Weight Loss Program: Subscription-based telemedicine service providing GLP-1 weight loss medications (Mounjaro, Ozempic, semaglutide) with doctor consultations, lab work coordination, insurance navigation, and ongoing care management. Revenue generated through insurance billing and patient subscription fees.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Next Medical operated a direct-to-consumer telemedicine platform that connected patients with physicians for weight loss treatment using GLP-1 medications such as Mounjaro, Ozempic, and semaglutide. Services included online intake, lab testing coordination through Labcorp and Quest Diagnostics, insurance prior authorization handling, telemedicine consultations, prescription management, and 24/7 customer support.

Product overview

Next Medical operated as a telemedicine healthcare company offering a unified weight loss program that combined virtual physician consultations, GLP-1 medication prescriptions (including Mounjaro, Ozempic, and compounded semaglutide), and lab testing services. The platform integrated with national laboratory providers Labcorp and Quest to facilitate blood work and diagnostic testing. Patients accessed care through an online portal with support from customer service representatives and healthcare providers. The company served individuals seeking medical weight loss solutions, with services including insurance navigation, prior authorization assistance, and ongoing medication management.

Differentiator

Problem solved

Functional benefit

Products and services

• Weight Loss Program A telemedicine-delivered weight loss program providing access to GLP-1 medications (Mounjaro, Ozempic, semaglutide) combined with physician consultations, lab testing through partner facilities, insurance navigation, and ongoing support for individual patients seeking medical weight loss.
• Telemedicine Platform An online healthcare platform enabling virtual doctor consultations, prescription management, patient-provider communication, lab ordering integrated with Labcorp and Quest Diagnostics, and intake processing for individual patients enrolled in the weight loss program.

Quantifiable outcome

• 390,000+ people helped find healthcare solutions
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• LabcorpcoreTechnology or IntegrationPartnership with Labcorp for laboratory testing services. NextMed facilitated 1,000,000s of lab tests through this partnership, enabling patients to access diagnostic services as part of their weight loss program.
• Quest DiagnosticscoreTechnology or IntegrationPartnership with Quest Diagnostics for laboratory testing services. Combined with Labcorp partnership, this enabled 1,000,000s of lab tests and prescriptions made more accessible to patients.

Scale indicators6 records

Recent moves7 records

Direct peers

• Calibrate: Calibrate is a DTC metabolic health company combining telemedicine with GLP-1 prescriptions and lifestyle coaching for weight loss. It is one of the most direct comparables to NextMed in business model, customer segment, and product offering.
• Ro: Ro operates a direct-to-patient telehealth platform offering weight loss programs including GLP-1 medications via its Body Program. It competes with NextMed on the same DTC prescription-based weight loss use case, with deeper capital and broader condition coverage.
• Hims & Hers Health: Hims & Hers is a public DTC telehealth company offering prescription weight loss treatments including GLP-1s alongside a broad portfolio of men's and women's health products. It is a scaled competitor in the same category with materially more resources.
• Found: Found is a DTC weight management company combining physician consultations with prescription medication (including GLP-1s). It overlaps directly with NextMed's telehealth prescribing model and target patient segment.
• Sequence (WeightWatchers): Sequence was acquired by WeightWatchers to offer telehealth-based GLP-1 prescriptions, directly competing in the same prescription weight loss category. WW provides broader brand and behavioral program assets behind the same drug-prescribing model.
• Form Health: Form Health is a physician-led telemedicine platform delivering medical obesity treatment including GLP-1 medications. It targets a similar patient segment with a more clinician-led, longitudinal-care orientation than NextMed.
• Noom: Noom is a behavior-change weight management platform that has expanded into prescription weight loss with Noom Med. It competes with NextMed in the same end-customer use case but combines lifestyle coaching with medication.
• Lemonaid Health: Lemonaid Health operates a DTC telemedicine platform with online consultations and prescription fulfillment across multiple conditions. It overlaps NextMed in telehealth-based prescribing and pharmacy integration, though with a broader condition scope.

Emerging players

• Eden: Eden offers direct-to-patient access to GLP-1 medications via telehealth with emphasis on clinician oversight. It is an emerging competitor in the same niche with a more limited operational footprint than NextMed had.

Broad incumbents

• Teladoc Health: Teladoc is a large incumbent telehealth platform offering general virtual care including chronic condition management. It is comparable as a broad platform where NextMed specialized in a single condition category.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/Next-Medical-104600488154309
• LinkedInlinkedin.com/company/joinnextmed

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Next Medical